Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.06 | 0.2 |
mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.036 | 0.2 |
mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.058 | 0.2 |
mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |